A Phase 2 Trial Evaluating Safety and Tolerability of RCT2100
Phase 2
192
about 2.9 years
18–60
13 sites in AL, AZ, CA +9
What this study is about
Researchers are testing the safety and tolerability of a new treatment, RCT2100, in healthy people and people with cystic fibrosis. The trial will involve different doses of RCT2100 administered through inhalation, either alone or with ivacaftor.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Placebo
- 2.Take Ivacaftor
- 3.Take RCT2100
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
ivacaftor
oral (Oral Tablet)
Primary: Part 1: The number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)., Part 2: The number of participants with CF with AEs and SAEs., Part 3: The number of participants with CF with AEs and SAEs.
Respiratory